April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
A Comparative Study Of The Effect Of Brimonidine, Fenretinide and Valproate On Light-induced Retinal Degeneration
Author Affiliations & Notes
  • Ronald Lai
    Biological Sciences, Allergan, Inc, Irvine, California
  • Raymond Lim
    Biological Sciences, Allergan, Inc, Irvine, California
  • George Wu
    Biological Sciences, Allergan, Inc, Irvine, California
  • Jeffrey L. Edelman
    Biological Sciences, Allergan, Inc, Irvine, California
  • Footnotes
    Commercial Relationships  Ronald Lai, Allergan (E); Raymond Lim, Allergan (E); George Wu, Allergan (E); Jeffrey L. Edelman, Allergan (E)
  • Footnotes
    Support  Allergan
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5466. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ronald Lai, Raymond Lim, George Wu, Jeffrey L. Edelman; A Comparative Study Of The Effect Of Brimonidine, Fenretinide and Valproate On Light-induced Retinal Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5466. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : It has been suggested that brimonidine, fenretinide and valproate may have beneficial effects for the treatment of retinal degeneration. Since these agents have different pharmacological properties, it is believed that they mediate retinal protection via different mechanisms. In this study, we examined and compared the effect of these compounds in the blue light-induced retinal degeneration rat model.

Methods: : Male Spraque-Dawley rats were dosed daily for 10 days with either brimonidine (1 mg/kg ip), fenretinide (5 mg/kg oral), or sodium valproate (250 mg/kg ip). Vehicle-treated animals served as controls. On the third dosing day, the animals were dark adapted for 24 hours and then exposed to 8 hours of blue light (4000 lux). The change in retinal function of these animals was evaluated using electroretinography (ERG) after 7 days of recovery period. Histologic assessment of the light-induced retinal damage was performed on the sections of paraffin-embedded eyes. Evaluation of the cone photoreceptor damage was performed on PNA-stained retinal flatmounts.

Results: : Seven days after blue light exposure, the photoreceptor layer in the superior side of the retina was reduced from 12 rows of cells to 1 row, and ERG a-wave was decreased by 80%. Number of healthy cone photoreceptor was significantly reduced in the superior retina. Increased autofluorescence deposits were also observed at the RPE/photoreceptor layers. At 1 mg/kg dose, brimonidine protected the photoreceptor layer by 45% and the ERG a-wave by 50%. At 5 mg/kg dose, fenretinide provided 26% protection in the outer nuclear layer and 30% protection in ERG a-wave amplitude, compared with controls. However, no observable difference was found between vehicle-treated animals and valproate-treated animals.

Conclusions: : Both brimonidine and fenretinide (but not valproate) significantly ameliorate photoreceptor damage in this blue light-induced retinal degeneration model. Brimonidine appears to be more efficacious than fenretindie in protecting the photoreceptor, which may be due to the different protective mechanisms mediated by these two agents.

Keywords: retinal degenerations: cell biology • neuroprotection • photoreceptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×